Morphine
23 June, 2023
Nabumetone
23 June, 2023
Mycapssa
Generic name: Octreotide acetate
Drug class: Somatostatin analog
Dosage form: Delayed-release oral capsule
Route of administration: Oral
Dose: The recommended initial dose is 40 mg daily, administered as 20 mg orally twice daily. The maximum recommended dosage is 80 mg daily, administered as 40 mg twice daily. Dosage adjustments may be necessary based on individual patient response and tolerability.
Mechanism of action: Octreotide acetate is a synthetic octapeptide that mimics the action of somatostatin, inhibiting the secretion of growth hormone and other hormones, thereby reducing the production of insulin-like growth factor 1 (IGF-1) in patients with acromegaly.
Drug usage cases:
- Long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Drug contraindications:
- Hypersensitivity to octreotide or any of the components of MYCAPSSA.
Side effects:
- Nausea
- Diarrhea
- Headache
- Arthralgia
- Asthenia
- Hyperhidrosis
- Peripheral swelling
- Increased blood glucose levels
- Vomiting
- Abdominal discomfort
- Dyspepsia
- Sinusitis
- Osteoarthritis
Warnings:
- MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.
- Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.
- Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.
- New onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.
Use during pregnancy or breastfeeding: MYCAPSSA has not been studied in pregnant or breastfeeding women. It is not known whether MYCAPSSA can harm a fetus or pass into breast milk. Women who are pregnant or breastfeeding should consult their healthcare provider before using MYCAPSSA.
